Protalix Biotherapeutics Stock Price Prediction
| PLX Stock | USD 2.33 0.00 0.00% |
Momentum 66
Buy Stretched
Oversold | Overbought |
Quarterly Earnings Growth (0.39) | EPS Estimate Next Quarter 0.08 | Wall Street Target Price 14.5 | EPS Estimate Current Quarter 0.04 | Quarterly Revenue Growth 0.736 |
Using Protalix Biotherapeutics hype-based prediction, you can estimate the value of Protalix Biotherapeutics from the perspective of Protalix Biotherapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Protalix Biotherapeutics using Protalix Biotherapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Protalix using crowd psychology based on the activity and movement of Protalix Biotherapeutics' stock price.
Protalix Biotherapeutics Implied Volatility | 1.5 |
Protalix Biotherapeutics' implied volatility exposes the market's sentiment of Protalix Biotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Protalix Biotherapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Protalix Biotherapeutics stock will not fluctuate a lot when Protalix Biotherapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Protalix Biotherapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Protalix because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Protalix Biotherapeutics after-hype prediction price | USD 2.32 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Protalix |
Protalix Biotherapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Protalix Biotherapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Protalix Biotherapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Protalix Biotherapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Protalix Biotherapeutics Estimiated After-Hype Price Volatility
In the context of predicting Protalix Biotherapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Protalix Biotherapeutics' historical news coverage. Protalix Biotherapeutics' after-hype downside and upside margins for the prediction period are 0.12 and 5.47, respectively. We have considered Protalix Biotherapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Protalix Biotherapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Protalix Biotherapeutics is based on 3 months time horizon.
Protalix Biotherapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Protalix Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protalix Biotherapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Protalix Biotherapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.60 | 3.15 | 0.01 | 0.02 | 4 Events / Month | 9 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.33 | 2.32 | 0.43 |
|
Protalix Biotherapeutics Hype Timeline
On the 27th of February Protalix Biotherapeutics is traded for 2.33. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.02. Protalix is expected to decline in value after the next headline, with the price expected to drop to 2.32. The average volatility of media hype impact on the company price is over 100%. The price depreciation on the next news is expected to be -0.43%, whereas the daily expected return is at this time at 0.6%. The volatility of related hype on Protalix Biotherapeutics is about 9450.0%, with the expected price after the next announcement by competition of 2.31. About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.15. Protalix Biotherapeutics last dividend was issued on the 20th of December 2019. The entity had 1:10 split on the 20th of December 2019. Considering the 90-day investment horizon the next expected press release will be in about 4 days. Check out Protalix Biotherapeutics Basic Forecasting Models to cross-verify your projections.Protalix Biotherapeutics Related Hype Analysis
Having access to credible news sources related to Protalix Biotherapeutics' direct competition is more important than ever and may enhance your ability to predict Protalix Biotherapeutics' future price movements. Getting to know how Protalix Biotherapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Protalix Biotherapeutics may potentially react to the hype associated with one of its peers.
Protalix Biotherapeutics Additional Predictive Modules
Most predictive techniques to examine Protalix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Protalix using various technical indicators. When you analyze Protalix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Protalix Biotherapeutics Predictive Indicators
The successful prediction of Protalix Biotherapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Protalix Biotherapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Protalix Biotherapeutics based on analysis of Protalix Biotherapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Protalix Biotherapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Protalix Biotherapeutics's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 3.34 | 5.32 | 4.79 | 5.03 | Days Of Inventory On Hand | 313.06 | 302.47 | 272.23 | 366.4 |
Story Coverage note for Protalix Biotherapeutics
The number of cover stories for Protalix Biotherapeutics depends on current market conditions and Protalix Biotherapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Protalix Biotherapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Protalix Biotherapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Protalix Biotherapeutics Short Properties
Protalix Biotherapeutics' future price predictability will typically decrease when Protalix Biotherapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Protalix Biotherapeutics often depends not only on the future outlook of the potential Protalix Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protalix Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 82.4 M | |
| Cash And Short Term Investments | 44.6 M |
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.